Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
334.85
0.00 (0.00%)
Oct 3, 2024, 8:31 AM EST - Market open

Company Description

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.

It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories.

The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers.

Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories logo
Country United States
Founded 1952
Industry Medical Devices
Sector Healthcare
Employees 8,030
CEO Norman Schwartz

Contact Details

Address:
1000 Alfred Nobel Drive
Hercules, California 94547
United States
Phone 510 724 7000
Website bio-rad.com

Stock Details

Ticker Symbol BIO.B
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000012208
CUSIP Number 090572108
ISIN Number US0905721082
Employer ID 94-1381833
SIC Code 3826

Key Executives

Name Position
Norman D. Schwartz Chairman and Chief Executive Officer
Jonathan P. DiVincenzo President and Chief Operating Officer
Tania DeVilliers Senior Director, Corporate Controller and Interim Principal Accounting Officer
Yong Chung Vice President of Investor Relations
Matthew Werner Senior Vice President and Chief Compliance and Privacy Officer
Courtney C. Enloe Executive Vice President, General Counsel and Secretary
Colleen Corey Executive Vice President of Global Human Resources
Michael Crowley Executive Vice President of Global Commercial Operations
Lee Boyd Senior Vice President of Global Commercial Operations - Asia Pacific
James J. Barry Executive Vice President and President of Life Science Group

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 144 Filing
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 31, 2024 10-Q Quarterly Report
Oct 30, 2024 8-K Current Report
Oct 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 10, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals